CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Value of SMAD4 in patients with advanced colorectal cancer (aCRC) receiving an oxaliplatin containing first line chemotherapy – a study of the AIO colorectal cancer group (AIO)
DOI 10.1055/s-0029-1241638
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA Baraniskin, D Meier, K Schulmann, HT Arkenau, U Graeven, R Poschen, W Schmiegel, A Tannapfel, A Reinacher-Schick
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe09/2009
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: The tumor suppressor SMAD4 is implicated in the development and progression of colorectal cancer (CRC). Its role as a prognostic marker in patients with CRC is poorly defined. We investigated the prognostic value of Smad4 loss in aCRC patients treated with an oxaliplatin containing first line chemotherapy regimen. Methods: Tissue samples were obtained from patients who took part in a randomized phase I…
Zitieren
Zitierempfehlung
A Baraniskin, D Meier, K Schulmann, HT Arkenau, U Graeven, R Poschen, W Schmiegel, A Tannapfel, A Reinacher-Schick (2009) Value of SMAD4 in patients with advanced colorectal cancer (aCRC) receiving an oxaliplatin containing first line chemotherapy – a study of the AIO colorectal cancer group (AIO). Zeitschrift für Gastroenterologie (09). https://doi.org/10.1055/s-0029-1241638
Mit CareLit weiterarbeiten